Cultivation Process of Reishi-MRL™
Mycology Research Laboratories Ltd.´s Ganoderma lucidum, is grown on a sterilised (autoclaved) substrate under ISO 22000:2018 standards in the EU.
This cultivation process ensures the powder complies with the EU regulation 1881/2006 for contamination of pesticides and heavy metals. The cultivation system is proprietary, allowing for standardised production of Ganoderma lucidum.
MRL mushrooms biomass offers a mixture of many co-operating and co-related healthful bioavailable ingredients prepared by nature itself – it is thus a truly pure natural product.
After cultivation the Ganoderma lucidum is then manufactured in the Netherlands into 500 mg tablets and in various powder forms to FSSC 22000 (Version 4.1) standards.
Veterinary products are manufactured under veterinary registration number (NL217476).
Moreover, all powder presentations are produced and manufactured in accordance with both EU and UK organic standards.
Chemical and Biological Properties *
Each Tablet of Reishi-MRL contains
| Ganoderma lucidum - biomass powder | 500 mg |
Other ingredients
| Microcrystalline Cellulose |
| Silica |
| Vegetable Magnesium Sterate |
Reishi-MRL - Enzyme Activity Per 750 mg Tablet
| Protein content | 22.2 mg |
| Reducing sugars | 24.0 mg |
| Protein-bound polysaccharide | 69.5 mg |
| Glucose 2-oxidase activity | 8.2 mU |
| Peroxidase activity | 11.2 mU |
| Laccase activity | 451.5 mU |
| Glucoamylase / beta-glucansase activity | 2.7 U |
| Protease activity | 4.4 mU |
| Superoxide dismutase (SOD) activity | 50.4 mU |
| Cytochrome P-450 | 0.66 nmoles |
| Cytochrome P-450 reductase | 7.05 mU |
| Secondary metabolites (Thrombin inhibitors) | 4.4% |